Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
Actavis and Teva sued over narcotic addiction generic
01-03-2017
madamF / Shutterstock.com
The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s (PTAB) decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, PTAB, Alan Lourie, William Bryson and Kathleen O’Malley, Teva Pharmaceutical, McKool Smith
